SEC Filings
Foghorn’s $83.5 Million Revenue Includes $74.1 Million Accounting Catch-Up As It Refocuses Research
The company is prioritizing wholly owned bowel-disease and cancer programs, with cash it expects to last into the second half of 2029.
SEC Filings
The company is prioritizing wholly owned bowel-disease and cancer programs, with cash it expects to last into the second half of 2029.
SEC Filings
The higher dose preserved responses in rheumatoid arthritis, while further development in Sjögren’s disease looks unlikely.
SEC Filings
AppLovin’s disclosed value fell to $1.5 billion, while Baillie Gifford increased its Lam Research and Arm holdings.
SEC Filings
The proposed convertible notes would also repay existing debt, while a separate lender agreement loosens borrowing limits.
SEC Filings
The company plans to ask whether approval is possible without additional clinical studies; the FDA raised no safety concerns.
SEC Filings
The forecast rests on offering proceeds, existing cash, spending discipline and access to further share sales.
SEC Filings
The company targets an FDA application by year-end 2026 to reach patients receiving BCG for the first time.
SEC Filings
Expected sale proceeds support $3 billion in buybacks across 2026 and 2027, plus $3 billion of planned debt reduction in 2027.
SEC Filings
The loan agreement offers another $835.0 million in delayed funding and requires no collateral or subsidiary guarantees.
SEC Filings
The new bonds mature in 2034 and carry a 7.125% rate, compared with 5.50% on the $500 million of notes slated for redemption.
SEC Filings
The purchase uses Friday’s closing price, while future repurchases must leave Argon’s recorded stake at or below 14.9%.
SEC Filings
Small uncontrolled studies also showed lupus kidney responses and systemic sclerosis improvement, with a myositis approval filing planned for 2028.